1. Matthews G, Borok M, Kaplan R, et al. D2EFT: dolutegravir and darunavir evaluation in adults failing first-line HIV therapy. Programme and Abstract to the 30th Conference on HIV and Opportunistic Infections, 19-23 Feb 2023, Seattle, USA; Oral Abstract 198.
2. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial;Aboud;Lancet Infect Dis,2019
3. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial
4. Squires K.E, Correll TA CorreRobertson MK et al, Effect of islatravir on total lymphocyte count and lymphocyte subset count. Programme and Abstract to the 30th Conference on HIV and Opportunistic Infections, 19-23 Feb 2023, Seattle, USA. Abstract 192.
5. Mills AM, Osiyemi O, Correll TA, et al. Switch to DOR/ISL (100/0.mg) QD from B/F/TAF: week 48 results from a phase 3 trial. Programme and Bstract to the 30th Conference on HIV and Opportunistic Infections, 19-23 Feb 2023, Seattle, USA; Oral Abstract 198.